Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. (Q34619574)

3 August 2017

1 reference

title

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. (English)

1 reference

3 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Nicholas J. Vogelzang

series ordinal

3

object named as

Nicholas J Vogelzang

1 reference

3 August 2017

Neeraj Agarwal

1

1 reference

3 August 2017

Thomas E Hutson

series ordinal

2

1 reference

3 August 2017

Guru Sonpavde

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

3 August 2017

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

665-679

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

3 August 2017

cites work

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

21 January 2018

1 reference

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

21 January 2018

1 reference

The case for secondary hormonal therapies in the chemotherapy age.

21 January 2018

1 reference

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

21 January 2018

1 reference

CYP17 inhibition as a hormonal strategy for prostate cancer.

21 January 2018

1 reference

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

21 January 2018

1 reference

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

21 January 2018

1 reference

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

21 January 2018

1 reference

PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer

21 January 2018

1 reference

BCL-2 in prostate cancer: a minireview

21 January 2018

1 reference

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

21 January 2018

1 reference

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

21 January 2018

1 reference

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

21 January 2018

1 reference

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

21 January 2018

1 reference

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

21 January 2018

1 reference

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

21 January 2018

1 reference

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure

21 January 2018

1 reference

Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer

21 January 2018

1 reference

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

Humors of tumors: potential for interaction between cancer type and treating oncologist's personality?

21 January 2018

1 reference

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

Emerging biological observations in prostate cancer

21 January 2018

1 reference

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

21 January 2018

1 reference

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

21 January 2018

1 reference

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer

21 January 2018

1 reference

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

21 January 2018

1 reference

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

21 January 2018

1 reference

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

21 January 2018

1 reference

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

21 January 2018

1 reference

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

Genomic strategy for targeting therapy in castration-resistant prostate cancer

21 January 2018

1 reference

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.48

1 reference

3 August 2017

1 reference